Schwann cells derived from neonatal skin-derived precursors (SKP-SCs) or neonatal peripheral nerve

Biologic · Cell therapy with no ChEMBL entity, so ChEMBL was NOT queried; resolved=false by modality. STRONG MODALITY MATCH, one of the better translations in this batch: all 7 recorded trials are autologous human Schwann cell (ahSC) products from the same Miami Project / W. Dalton Dietrich programme, in peripheral nerve injury and spinal cord injury, i.e. exact injury indications. IMPORTANT DIFFERENCE recorded knowingly: the human product is expanded from ADULT AUTOLOGOUS peripheral nerve, NOT from neonatal skin-derived precursors; no human trial uses SKP-derived Schwann cells. 3 of the 7 are EXPANDED ACCESS records with status NO_LONGER_AVAILABLE and no enrolment, so the interventional evidence base is 4 Phase 1 studies totalling roughly 52 planned participants.